Workforce – Talk Bio

2025 FDA staff cuts and their impact on new drug review timelines

2 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

2 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

2 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

2 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

Major Leadership Changes and Fundraising in Biotech: Metagenomi CEO Exit, Workforce Cuts; Cogent Biosciences Raises Over $475M

2 months ago talkbio0Tagged bezuclastinib, Brian Thomas, CEO, Cogent Biosciences, Exit, Fund Raising, hemophilia A program, Irish (ethnic group), Jian, layoffs, Metagenomi, pipeline focus, Workforce

Metagenomi; CEO exit; Brian Thomas; Jian Irish; workforce cuts; biotech layoffs; Cogent Biosciences; fundraising; bezuclastinib; hemophilia A program; pipeline focus

Ferring to Downsize by 500 Staffers in Global Reorganization Effort

4 months ago talkbio0Tagged enterprise reorganization, Ferring, headcount, layoffs, optimisation programme, Pharma, staff reduction, Workforce

Ferring; layoffs; staff reduction; optimisation programme; enterprise reorganization; pharma; headcount; workforce restructuring

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

1 year ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy